Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
European Journal of Medicinal Chemistry|December 26, 2021
DYRK1A inhibitors for disease therapy: Current status and perspectivesTong Liu, Yuxi Wang, Jiaxing Wang, et al.European Journal of Medicinal Chemistry|July 22, 2022
Current progress and novel strategies that target CDK12 for drug discoveryPeng Lei, Jifa Zhang, Peiyu Liao, et al.European Journal of Medicinal Chemistry|September 14, 2023
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospectsJinxiao Ru, Yuxi Wang, Zijia Li, et al.Future Medicinal Chemistry|October 18, 2025
Dual inhibition of BRAF for cancer treatment: advances and therapeutic potentialChangyu Ren, Mansi Zhang, Jiao Liu, et al.Journal of Medicinal Chemistry|August 25, 2022
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease TherapyYingxu Fang, Jiaxing Wang, Min Zhao, et al.Chemico-Biological Interactions|April 17, 2026
The Mechanistic Nexus Between Microplastics and Chronic Liver Disease: A Review of Current EvidenceShiyun Pu, Changyu Ren, Jiao Liu, et al.Cardiovascular Toxicology|October 17, 2025
Argatroban-Associated Adverse Events: An Analysis Based on FDA Adverse Event Reporting System (FAERS)Changyu Ren, Guimu Guo, YiXuan Wang, et al.European Journal of Medicinal Chemistry|February 12, 2022
Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectivesLele Zhang, Jifa Zhang, Jiaxing Wang, et al.European Journal of Medicinal Chemistry|May 15, 2022
Targeting EZH2 for cancer therapy: From current progress to novel strategiesJia Zeng, Jifa Zhang, Ying Sun, et al.Life Sciences|October 15, 2020
Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activationYuanxin Guo, Xiaohong Gan, Houfeng Zhou, et al.Pageof 3